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Skin and Soft 
Tissue Infections 
and Vascular 
Disease among 
Drug Users, England 
To the Editor: The injecting of 
illicit drugs is associated with skin and 
soft tissue infections (SSTIs) and vas-
cular disease (1–3). These conditions 
include the development of cutaneous 
abscess and cellulitis at injection sites, 
from subcutaneous or intramuscular 
injecting, known as skin and muscle 
popping, and intravenous injecting 
(1–3). Intravenous injection is asso-
ciated with phlebitis or thrombophle-
bitis, in which the vein may become 
infected (4). Inadvertent arterial injec-
tion, particularly when attempting to 
inject into the femoral vein, that is, 
“groin injecting,” may cause arterial 
pseudoaneurysm (4,5).
Drug-related conditions form a 
major part of the workload of some 
hospital emergency departments in the 
United Kingdom and elsewhere (1–
3,6). We aimed to identify emerging 
trends in hospital admission for SSTIs 
and vascular disease arising from drug 
use and, speciﬁ  cally, where these may 
have occurred after injection of the 
femoral vein.
We extracted hospital admis-
sion data for drug users 15–44 years 
of age for the ﬁ   scal years April 1, 
1997–March 31, 2004, from the UK 
Department of Health, hospital epi-
sode statistics (HES) database. Using 
the International Classiﬁ  cation of Dis-
eases, 10th revision (ICD-10) codes 
F11–16, F18, and, F19, we identiﬁ  ed 
drug users by a record in any diagnos-
tic ﬁ  eld of mental and behavioral dis-
orders due to psychoactive substances, 
excluding alcohol and tobacco. We 
identiﬁ   ed the primary diagnosis on 
admission and whether the admission 
was as an emergency.
Over the study period, admissions 
of drug users for cutaneous abscess, 
L020–L029; cellulitis, L030–L039; 
and phlebitis or thrombophlebitis, 
I801–I809; increased substantially 
(online Appendix Figure, available 
from www.cdc.gov/EID/content/13/
10/1510-appG.htm). Increases oc-
curred in speciﬁ  c primary diagnoses 
from 1997–1998 to 2003–2004; the 
largest percentage increase was for 
phlebitis or thrombophlebitis of the 
femoral vein, I801, from 60 to 533 
(788%). Increases were also observed 
for aneurysm or pseudoaneurysm of 
an artery of a lower limb, I724, from 
9 to 62 (589%), cutaneous abscess of 
trunk or groin, L022, from 92 to 613 
(566%), cellulitis of trunk or groin, 
L033, from 13 to 74 (469%), and, 
phlebitis or thrombophlebitis of deep 
vessels of the lower limb other than 
the femoral vein, I802, from 269 to 
1,314 (388%).
No national data exist for the 
prevalence of injection drug use in 
England (7). Although the number of 
opiate injecting drug users may have 
increased in the 1990s (8), the rapid 
and substantial increase in admissions 
for SSTIs and vascular disease sug-
gests that this has not resulted from 
an increase in the injecting population 
alone.
The contribution to the increase in 
admissions from subcutaneous or mus-
cle injecting and intravenous injecting 
cannot be determined from these data. 
The increases for phlebitis or throm-
bophlebitis of the femoral vein and 
aneurysm or pseudoaneurysm of the 
lower limb suggest that groin inject-
ing may have contributed to the study 
ﬁ  ndings (9). The choice of drugs may 
have contributed to our ﬁ  ndings. An 
association between injecting site in-
fections in England has been reported 
with crack cocaine injection and else-
where with cocaine injection (2,3,7).
This study has some limitations. 
The HES database does not distin-
guish between injection and noninjec-
tion drug users and whether injection 
was intravenous or subcutaneous and 
intramuscular. The study does not re-
late HES data entries to the conditions 
described directly by the physical ex-
amination of patients or the review of 
clinical notes. Those conditions asso-
ciated with femoral vein injection do 
not exclusively result from this prac-
tice, and the proportion of these ad-
missions not associated with injection 
drug use is unknown. The study period 
was limited by date of the introduction 
of ICD-10 coding; therefore, earlier 
trends could not be identiﬁ  ed. Never-
theless, this analysis highlights a po-
tentially important trend and the need 
for further quantitative and qualitative 
research in injection drug users.
The response to these problems 
could be addressed by changing be-
havior and improving access to health-
care (1). Ideally, injection drug users 
(IDUs) should have early entry to, and 
be retained on, substance abuse treat-
ment, particularly methadone mainte-
nance (1). Skin and muscle injecting, 
and injecting into the femoral vein 
should be discouraged (3). To inject 
safely, IDUs need access to clean 
equipment to prevent the use of shared 
and dirty needles and the reuse of sy-
ringes. Injection sites should be ro-
tated, the skin should be cleaned with 
alcohol, and the licking of needles and 
booting  should be discouraged (1–3). 
Patients were predominantly admit-
ted through emergency departments, 
which suggests poor contact with 
health services and reluctance to seek 
treatment until the point of crisis (10). 
Early medical treatment is required, 
possibly with the creation of hospital-
based SSTI clinics, as were success-
fully introduced in San Francisco, or 
improved community outreach (1).
In summary, this study identi-
ﬁ  es a rapid and important increase in 
the hospitalization of drug users in 
England for SSTIs and vascular con-
ditions. Further work is required to 
obtain more information about these 
clinical problems and the patients’ as-
sociated lifestyle, on admission and 
in the community. Means of discour-
aging risk-related behavior and treat-
ment should be implemented before LETTERS
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the conditions require urgent hospital 
admission.
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